Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 October 2020 | Story Leonie Bolleurs | Photo Supplied
ARU Researchers on mountain slope
A team of international researchers discovered in March 2020 a new grass species, Festuca drakensbergensis, during extensive fieldwork in the 40 000 km2 Maloti-Drakensberg area.

In their search to learn more about the impact of humans and climate change on grasses in the Drakensberg Mountain Centre (DMC), one of the most studied mountain systems in the region, a group of scientists found a new grass species, which they named Festuca drakensbergensis (common name unknown; herein could be designated the ‘Drakensberg Alpine Fescue’).

The team who is working on the project includes Dr Vincent R. Clark, Head of the Afromontane Research Unit at the University of the Free State (UFS), Prof Steven P. Sylvester from the Nanjing Forestry University in Nanjing, Jiangsu, China, and Dr Robert J. Soreng, working in the Department of Botany at the Smithsonian Institution in Washington DC.

 

The discovery

The species, that was discovered in March 2020, was found during extensive fieldwork and herbarium research across the 40 000 km2 Maloti-Drakensberg area. The DMC has a very high endemic plant diversity, says Dr Clark.

He goes on to say that the DMC has a Montane Sub-Centre (below 2800 m) and an alpine sub-centre (above 2800 m). “It is the only mountain system in Africa south of Mt Kilimanjaro with an alpine component,” he adds.

ProfSylvester says the species was easily recognisable during their fieldwork, being found fairly common throughout the Afro-alpine landscape. Although at that point they only knew it to be a distinct taxon, they realised that the species was new to science when they tried to identify it and compared it with other closely related Festuca taxa.

Besides this discovery, the team also reinstated two varieties of Festuca caprina and rediscovered the overlooked F. exaristata, all of them endemic to the DMC. Prof Sylvester believes that this discovery highlights the importance of these high-elevation ecosystems as harbours of unique biodiversity that require focused conservation efforts.

Although grasses are a dominant species that control the ecosystem function in the Afro-alpine grasslands, they are the least known of all plant species found in these ecosystems. Up until now there has been a lack of focused research on Afro-alpine grasses.

 “We provide a taxonomic reappraisal of the Festuca caprina complex that will aid future ecological and biogeographical research in the DMC and allow us to better understand the complexities of these ecosystems and how to conserve and manage them,” says Prof Sylvester.

 

This discovery highlights the importance of these high-elevation ecosystems as harbours of unique biodiversity that require focused conservation efforts. - Prof Steven Sylvester

 

 

Adding value

According to Dr Clark, the species contributes to the grazing and rangeland value of the Maloti-Drakensberg. “It also has functional value in terms of maintaining ecosystem integrity and associated water production landscape value in the area,” he says.

“The species seems fairly robust to pressures from grazing and burning, being found in both heavily grazed areas and semi-pristine areas, and may prove a useful species as part of a seed mix of native grasses for reseeding degraded Afro-alpine slopes and ski slopes,” mentions Prof Sylvester regarding the benefits of this indigenous species to the region.

The species is very common in Lesotho in Bokong Nature Reserve, Sehlabathebe National Park, and Sani Pass, and at Tiffendell and AfriSki ski resorts. Dr Soreng believes the species is likely to have a wider distribution range across the Maloti-Drakensberg, than what was documented before research was cut short due to the COVID-19 pandemic.

 

Next steps

According to Prof Sylvester, this taxonomic research feeds into a large-scale ecological study looking at the response of Afro-alpine ecosystems to different grazing and burning regimes that is being run in collaboration with Dr Clark at the ARU and Dr Soreng of the Smithsonian Institute, Washington DC.

“While our research has uncovered interesting novelties and provided a greater understanding of the taxonomy of grasses from high elevation Maloti-Drakensberg, there is still much to be done with regards taxonomic research of cool-season grasses in southern Africa,” says Prof Sylvester.

Dr Clark supports this notion and states that there is a major need for a better holistic understanding of the alpine zone in the Maloti-Drakensberg, given immediate pressures from over-grazing, land-use transformation, invasive species, and climate change.

“This is because the Maloti-Drakensberg is the most important water tower in southern Africa, providing water for some 30 million people in three countries. As the Maloti-Drakensberg is dominated by natural grasslands, understanding grass diversity and ecological behaviour is a primary need in the face of immediate human impacts and global change,” he says.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept